(Date:11/24/2009)..., Health care employment...mains the only one to show consistent growth durin...ty hospitals remain in trouble, and health systems...al personnel, instead of just administrators. , ...- Health care employment continued growing in Octo...
(Date:11/24/2009)..., , SAN MATEO, Calif., Nov. 24 /PRNew... ), a biopharmaceutical company focused on develop...apies, announced today that Anthony DiTonno, Presi...present at the 21st Annual Piper Jaffray Health Ca...e New York Palace Hotel in New York, New York. ,...
(Date:11/24/2009)..., The FBI recently approv...aboratories participating in or generating DNA rec... Madison, WI USA (PRWEB) -- The FB... HS System for use by laboratories participating ...A Index System (NDIS). NDIS currently contains mor...
(Date:11/24/2009)..., , DUBLIN, November 24 /PRNewswire-...), the global specialty biopharmaceutical company,...e European Medicines Agency for,velaglucerase alfa...lopment,for the treatment of Type 1 Gaucher diseas...aglucerase alfa that has been submitted, with prev...
Breaking Biology Technology:The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 2The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 3The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 4NeurogesX to Present at Piper Jaffray Health Care Conference 2NeurogesX to Present at Piper Jaffray Health Care Conference 3NDIS Approval of Promega PowerPlex Kit Clears Path for More DNA Profiles to be Added to U.S. Database 2Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 2Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 3Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 4...chnology Promises to Revolutionize Food Processing...-FirstCall/ - EnWave Corporation (TSX-V: ENW) ("En...s completed the first sale of its continuous nutra...rprises, Ltd. of Richmond, B.C. ("CAL-SAN"), one o...le, EnWave has proven that it can produce shelf-st...
...invivodata, inc., ( http://www.invivodata.com ) th...utcomes (ePRO) solutions and services for global c...ured presentations at upcoming international event...ta and its scientific and regulatory consulting di...rted.com ). , , Scientific, regulatory, and tech...
... Morphotek(R), Inc., a subsidiary of,Eisai Corpor...s commenced a,multi-centered Phase II study of its...e study will evaluate MORAb-009, plus the chemothe...line treatment for patients with,mesothelioma. , ... the efficacy of MORAb-009,as combination therapy ...
Other Biology Technology:EnWave Successfully Commercializes nutraREV(TM) Food Dehydration Technology 2EnWave Successfully Commercializes nutraREV(TM) Food Dehydration Technology 3EnWave Successfully Commercializes nutraREV(TM) Food Dehydration Technology 4invivodata and PRO Consulting to Present at International Industry Events 2invivodata and PRO Consulting to Present at International Industry Events 3Morphotek(R), Inc. Announces Initiation of MORAb-009 Phase II Study in First- Line Treatment of Mesothelioma 2Morphotek(R), Inc. Announces Initiation of MORAb-009 Phase II Study in First- Line Treatment of Mesothelioma 3...nt pigment lipofuscin accumulates in the cytoplasm...ce of lipofuscin granules can complicate the use o...ystem because of its broad excitation and emission...ly used fluorophores. The Autofluorescence Elimina...
DNA Sequencing Service from Yorkshire Bioscience Ltd
Rabbit Anti-Golgin-67 Polyclonal Antibody, Unconjugated from IMGENEX
Cytosol / Particulate Rapid Separation Kit from MBL International
Biology Products: